Abstract A15: A phase I and pharmacokinetic study of the vascular disrupting agent AVE8062 in combination with docetaxel, administered once every 3 weeks to patients with advanced solid tumors
Keyword(s):
Phase I
◽
2012 ◽
Vol 18
(5)
◽
pp. 1415-1425
◽